VIVA-GOH FOUNDATION PROFESSORSHIP IN PAEDIATRIC ONCOLOGY(2009)
The Viva Foundation for Children with Cancer was established in 2006 by Mrs Jennifer Yeo, who continues to serve as its Director and Chairman, to save the lives of children with cancer. The Goh Foundation was set up in 1994 by the founder of Wuthelam Holdings, Mr Goh Cheng Liang, a businessman and philanthropist. Together, the two foundations are committed to improving the quality of life of paediatric cancer patients by supporting initiatives in medicine, education and development.
Better treatments lead to better cures. Better research leads to better treatments. Hence Viva Foundation’s focus on life-saving innovative research, medical care and education to save the lives of children affected by cancer.
Viva’s multi-pronged approach to tackling paediatric cancer involves building strategic capacities and capabilities in Singapore. Among them are the Viva-University Children’s Cancer Centre, a one- stop treatment centre in NUH; Viva-NUS Centre for Translational Research in Acute Leukaemia; the Paediatric Oncology Nursing Course; the annual St Jude-Viva Forum, which brings together oncologists from around the world to exchange ideas and collaborate on research; and research programmes in Advanced Cellular Therapy, Cancer Immunology and Clinical Research.
With support from Viva Foundation and the Goh Foundation, NUS established the Viva-Goh Foundation Professorship in Paediatric Oncology. Cancer research is one of NUS’ flagship programmes. The Professorship helps advance knowledge in the treatment of childhood cancer, under the Viva Children’s Cancer Programme. A key breakthrough has been the use of genetic information to identify children with acute lymphoblastic leukaemia with a good prognosis, enabling effective treatments to be tailored so that the majority of children with favourable-risk leukaemia can be cured with minimal long term side-effects. The gift will also fund four research programmes in bone marrow transplant, childhood leukaemia, bone cancer and after-completion-of-therapy.